Table 1 In vitro urease Inhibition, anti-inflammatory, and cytotoxicity of synthetic compounds 3–27.
Compounds | R | Urease Inhibition Activity IC50 ± SEMa µM | Anti-Inflammatory Activity IC50 ± SDb µg/mL | Cytotoxicity (3T3 Cell line) IC50 ± SDb µM |
|---|---|---|---|---|
3 |
| Inactivec | Inactive | >30 |
4 |
| 38.8 ± 0.35 | Inactive | >30 |
5 |
| 36.5 ± 0.14 | 18.5 ± 1.0 | >30 |
6 |
| Insoluble | Inactive | >30 |
7 |
| 46.3 ± 0.43 | Inactive | >30 |
8 | 44.4 ± 0.43 | Inactive | >30 | |
9 |
| 14.2 ± 1.38 | 26.7 ± 2.5 | >30 |
10 |
| 15.7 ± 1.32 | Inactive | >30 |
11 |
| 13.2 ± 1.64 | Inactive | >30 |
12 |
| 12.3 ± 1.04 | 27.7 ± 2.4 | >30 |
13 |
| 13.6 ± 1.61 | Inactive | >30 |
14 |
| 35.8 ± 1.89 | Inactive | >30 |
15 |
| 34.1 ± 0.45 | Inactive | >30 |
16 |
| 21.5 ± 1.3 | 29.7 ± 1.7 | >30 |
17 |
| 14.7 ± 1.01 | 36.9 ± 3.0 | >30 |
18 |
| 26.3 ± 1.59 | Inactive | 29.5 ± 1.9 |
19 |
| 12.7 ± 0.8 | Inactive | >30 |
20 |
| 22.0 ± 1.15 | Inactive | >30 |
21 |
| 28.2 ± 1.48 | Inactive | >30 |
22 |
| 22.1 ± 1.91 | 25.1 ± 0.4 | >30 |
23 |
| 22.4 ± 1.83 | 12.3 ± 1.2 | >30 |
24 |
| 63.2 ± 2.0 | Inactive | >30 |
25 |
| Insoluble | Inactive | >30 |
26 |
| 46.8 ± 1.8 | 25.4 ± 1.3 | >30 |
27 |
| Insolubled | Inactive | >30 |
28 | Isoniazid(1) | Inactive | Inactive | 28.5 ± 1.2 |
29 | Thiourea (Standard) | 21.1 ± 0.2 (Observed) | — | — |
30 | Aetohydaoxamic acid (standard) | 20.3 ± 0.4 (Observed) 17.2 ± 0.9 (Reported) | ||
31 | Ibuprofen (Standard) | — | 11.2 ± 1.9 (observed) 12.97 ± 0.23 (reported) | — |
32 | Cyclohexanamide (Standard) | — | — | 0.8 ± 0.2 (observed) 0.26 ± 0.04 (reported) |
